ID   OPM-1
AC   CVCL_5210
SY   OPM1
DR   BioSample; SAMN10989618
DR   cancercelllines; CVCL_5210
DR   Cell_Model_Passport; SIDM00456
DR   Cosmic; 720768
DR   Cosmic; 2081431
DR   Cosmic; 2367299
DR   DepMap; ACH-000057
DR   Lonza; 28
DR   Wikidata; Q54936481
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3926660;
RX   PubMed=10087940;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32123307;
WW   Info; Keats Lab; -; https://www.keatslab.org/myeloma-cell-lines
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Characteristics: Produces Ig lambda.
CC   Doubling time: 36-42 hours (PubMed=3926660).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (DepMap=ACH-000057).
CC   Sequence variation: Mutation; HGNC; HGNC:3690; FGFR3; Simple; p.Lys650Glu (c.1948A>G); ClinVar=VCV000016331; Zygosity=Heterozygous (PubMed=11157491; DepMap=ACH-000057).
CC   Sequence variation: Mutation; HGNC; HGNC:6768; SMAD2; Simple; p.Leu87Arg (c.260T>G); Zygosity=Heterozygous (DepMap=ACH-000057).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (DepMap=ACH-000057).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Genome ancestry: African=0.52%; Native American=0%; East Asian, North=74.49%; East Asian, South=22.3%; South Asian=0%; European, North=0%; European, South=2.68% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Plasma cell; CL=CL_0000786.
ST   Source(s): Technion Genomics Center
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D10S1248: 14
ST   D12S391: 17,18
ST   D13S317: 11
ST   D16S539: 9,13
ST   D18S51: 13,14,15
ST   D19S433: 14,14.2
ST   D1S1656: 16,17.3
ST   D21S11: 30,33.2
ST   D22S1045: 11,17
ST   D2S1338: 19,25
ST   D2S441: 10
ST   D3S1358: 15,18
ST   D5S818: 13
ST   D7S820: 12
ST   D8S1179: 10,13
ST   FGA: 20,21
ST   Penta D: 9
ST   Penta E: 12,20,21
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1625 ! OPM-2
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 29
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler, Hans Gunther
RA   Matsuo, Yoshinobu
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   CelloPub=CLPUB00604;
RA   Chow, Sharon
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin, Vishesh
RA   Yu, Katharine
RA   Ferguson, Ian D.
RA   Gugliemini, Olivia
RA   Nix, Matthew A.
RA   Hann, Byron
RA   Sirota, Marina
RA   Wiita, Arun P.
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund, Helena
RA   Nilsson, Kenneth
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters, John R.W. & Palsson, Bernhard Orn (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi, Mahmoud
RA   Huang, Franklin W.
RA   Jane-Valbuena, Judit
RA   Kryukov, Gregory V.
RA   Lo, Christopher C.
RA   McDonald, E. Robert 3rd
RA   Barretina, Jordi Ginesta
RA   Gelfand, Ellen T.
RA   Bielski, Craig M.
RA   Li, Hao-Xin
RA   Hu, Kevin
RA   Andreev-Drakhlin, Alexander Y.
RA   Kim, Jaegil
RA   Hess, Julian M.
RA   Haas, Brian J.
RA   Aguet, Francois
RA   Weir, Barbara A.
RA   Rothberg, Michael V.
RA   Paolella, Brenton R.
RA   Lawrence, Michael Scott
RA   Akbani, Rehan
RA   Lu, Yi-Ling
RA   Tiv, Hong L.
RA   Gokhale, Prafulla C.
RA   de Weck, Antoine
RA   Mansour, Ali Amin
RA   Oh, Coyin
RA   Shih, Juliann
RA   Hadi, Kevin
RA   Rosen, Yanay
RA   Bistline, Jonathan
RA   Venkatesan, Kavitha
RA   Reddy, Anupama
RA   Sonkin, Dmitriy
RA   Liu, Manway
RA   Lehar, Joseph
RA   Korn, Joshua M.
RA   Porter, Dale A.
RA   Jones, Michael D.
RA   Golji, Javad
RA   Caponigro, Giordano
RA   Taylor, Jordan E.
RA   Dunning, Caitlin M.
RA   Creech, Amanda L.
RA   Warren, Allison C.
RA   McFarland, James M.
RA   Zamanighomi, Mahdi
RA   Kauffmann, Audrey
RA   Stransky, Nicolas
RA   Imielinski, Marcin
RA   Maruvka, Yosef E.
RA   Cherniack, Andrew D.
RA   Tsherniak, Aviad
RA   Vazquez, Francisca
RA   Jaffe, Jacob D.
RA   Lane, Andrew Alan
RA   Weinstock, David M.
RA   Johannessen, Cory M.
RA   Morrissey, Michael P.
RA   Stegmeier, Frank
RA   Schlegel, Robert
RA   Hahn, William Chun
RA   Getz, Gad
RA   Mills, Gordon B.
RA   Boehm, Jesse S.
RA   Golub, Todd Robert
RA   Garraway, Levi Alexander
RA   Sellers, William Raj
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler, Hans Gunther
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi, Marta
RA   Brents, Leslie A.
RA   Ely, Sarah A.
RA   Bais, Carlos
RA   Robbiani, Davide F.
RA   Mesri, Enrique A.
RA   Kuehl, Walter Michael
RA   Bergsagel, Peter Leif
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698;
RA   Keats, Jonathan J.
RA   Fonseca, Rafael
RA   Chesi, Marta
RA   Schop, Roelandt
RA   Baker, Angela
RA   Chng, Wee-Joo
RA   Van Wier, Scott
RA   Tiedemann, Rodger
RA   Shi, Chang-Xin
RA   Sebag, Michael
RA   Braggio, Esteban
RA   Henry, Travis
RA   Zhu, Yuan-Xiao
RA   Fogle, Homer
RA   Price-Troska, Tammy L.
RA   Ahmann, Gregory J.
RA   Mancini, Catherine
RA   Brents, Leslie A.
RA   Kumar, Shaji K.
RA   Greipp, Philip Robert
RA   Dispenzieri, Angela
RA   Bryant, Barb
RA   Mulligan, George
RA   Bruhn, Laurakay
RA   Barrett, Michael T.
RA   Valdez, Riccardo
RA   Trent, Jeffrey M.
RA   Stewart, A. Keith
RA   Carpten, John D.
RA   Bergsagel, Peter Leif
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184;
RA   Dib, Amel
RA   Gabrea, Ana
RA   Glebov, Oleg K.
RA   Bergsagel, Peter Leif
RA   Kuehl, Walter Michael
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=3926660; DOI=10.1002/ijc.2910360217;
RA   Katagiri, Shuichi
RA   Yonezawa, Takeshi
RA   Kuyama, Jun
RA   Kanayama, Yoshio
RA   Nishida, Kazuhiro
RA   Abe, Tatsuo
RA   Tamaki, Toshiharu
RA   Ohnishi, Mitsunobu
RA   Tarui, Seiichiro
RT   "Two distinct human myeloma cell lines originating from one patient
RT   with myeloma.";
RL   Int. J. Cancer 36:241-246(1985).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil, Julie
RA   Chen, Zhi-Hua
RA   Monteiro, Alvaro N.A.
RA   Teer, Jamie K.
RA   Eschrich, Steven A.
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5;
RA   Kuipers, Jeroen
RA   Vaandrager, Jan Willem
RA   Weghuis, Danielle Olde
RA   Pearson, Peter Lees
RA   Scheres, Jacques
RA   Lokhorst, Henk Martinus
RA   Clevers, Hans Cornelius
RA   Bast, Bert J.E.G.
RT   "Fluorescence in situ hybridization analysis shows the frequent
RT   occurrence of 14q32.3 rearrangements with involvement of
RT   immunoglobulin switch regions in myeloma cell lines.";
RL   Cancer Genet. Cytogenet. 109:99-107(1999).
//